Frederik Holst
Overview
Explore the profile of Frederik Holst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
511
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singer C, Holst F, Steurer S, Burandt E, Lax S, Jakesz R, et al.
Clin Cancer Res
. 2022 Aug;
28(18):4112-4120.
PMID: 35920686
Purpose: Estrogen receptor (ER) expression is a prognostic parameter in breast cancer, and a prerequisite for the use of endocrine therapy. In ER+ early breast cancer, however, no receptor-associated biomarker...
2.
Holst F, Werner H, Mjos S, Hoivik E, Kusonmano K, Wik E, et al.
Clin Cancer Res
. 2018 Nov;
25(1):334-345.
PMID: 30442683
Purpose: Amplification of , encoding the PI3K catalytic subunit alpha, is common in uterine corpus endometrial carcinoma (UCEC) and linked to an aggressive phenotype. However, it is unclear whether amplification...
3.
Mjos S, Werner H, Birkeland E, Holst F, Berg A, Halle M, et al.
Sci Rep
. 2017 Sep;
7(1):10240.
PMID: 28860563
Mutations of the phosphoinositide-3-kinase (PI3K) catalytic subunit alpha gene (PIK3CA) are frequent in endometrial cancer. We sequenced exon9 and exon20 of PIK3CA in 280 primary endometrial cancers to assess the...
4.
Holst F, Hoivik E, Gibson W, Taylor-Weiner A, Schumacher S, Asmann Y, et al.
Sci Rep
. 2017 Jul;
7:46873.
PMID: 28664899
This corrects the article DOI: 10.1038/srep25521.
5.
Halle M, Ojesina A, Engerud H, Woie K, Tangen I, Holst F, et al.
Am J Obstet Gynecol
. 2017 Jun;
217(4):432.e1-432.e17.
PMID: 28599900
Background: Cervical cancer is a major health problem worldwide. Identification of effective clinicopathologic and molecular markers is vital to improve treatment stratification. Objectives: The purpose of this study was to...
6.
Holst F, Singer C
Trends Endocrinol Metab
. 2016 Sep;
27(11):751-752.
PMID: 27595547
No abstract available.
7.
Gibson W, Hoivik E, Halle M, Taylor-Weiner A, Cherniack A, Berg A, et al.
Nat Genet
. 2016 Jun;
48(8):848-55.
PMID: 27348297
Recent studies have detailed the genomic landscape of primary endometrial cancers, but the evolution of these cancers into metastases has not been characterized. We performed whole-exome sequencing of 98 tumor...
8.
Holst F, Hoivik E, Gibson W, Taylor-Weiner A, Schumacher S, Asmann Y, et al.
Sci Rep
. 2016 Jun;
6:27960.
PMID: 27338572
No abstract available.
9.
Holst F, Hoivik E, Gibson W, Taylor-Weiner A, Schumacher S, Asmann Y, et al.
Sci Rep
. 2016 May;
6:25521.
PMID: 27160768
The estrogen receptor alpha (ERα) is highly expressed in both endometrial and breast cancers, and represents the most prevalent therapeutic target in breast cancer. However, anti-estrogen therapy has not been...
10.
Holst F
World J Clin Oncol
. 2016 Apr;
7(2):160-73.
PMID: 27081639
Twenty-five years ago, Nembrot and colleagues reported amplification of the estrogen receptor alpha gene (ESR1) in breast cancer, initiating a broad and still ongoing scientific debate on the prevalence and...